COVID-19
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for March 16, 2021.
German shepherds take down bad guys, dalmatians pull people from fires, beagles sniff out bombs and now llamas fight COVID-19.
A study published in the journal Nature suggest the U.K. strain may cause a 61% higher risk of 28-day mortality.
The COVID-19 pandemic is not only an international health crisis, but a burgeoning geopolitical exercise for Russia to win the hearts and minds of a large portion of the world while undermining the West.
With more European countries pausing dosing of AstraZeneca’s COVID-19 vaccine over concerns about potential blood clotting side effects, Russia is seeking to fill in the gaps with its Sputnik V vaccine.
EmpowerDX, a Eurofins subsidiary, just launched its direct-to-consumer COVID-19 Home Collection Kit in the U.S. through Amazon, making it one of a miniscule number of at-home and over-the-counter kits that are putting detection of the SARS-CoV-2 virus in the hands of patients.
Shares of GenMark Diagnostics are soaring in premarket trading after Roche announced it was acquiring the California-based company in a $1.8 billion deal to bolster its own diagnostics pipeline.
It was another busy week for clinical trial announcements. Here’s a look including trials for COVID-19, migraine, Parkinson’s disease, Alzheimer’s, HIV and more.
This morning, the World Health Organization issued a statement that there is no reason to stop using the vaccine because, as of this time, “no causal link has been established.”
While existing vaccines are being rolled out worldwide, Novavax’s is demonstrating effectiveness in late-stage trials and the partnership of Sanofi and Translate Bio is beginning early-stage trials for their mRNA vaccine.
PRESS RELEASES